ro oral semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients All about the Wegovy (semaglutide)

Patients with a del15q genotype tend to have higher BMI (137, 176, 177) and HbA1c levels, despite similar values of glycemia, insulinemia, insulin resistance, body composition, metabolic profile, adipocyte size, resting energy expenditure, hyperphagia score, and levels of ghrelin compared to those with mUPD, suggesting a possible association between mUPD genotype and a more adverse metabolic profile, even when adjusted for BMI

It is administered as a 16 mg subcutaneous implant every 2 months

Many initial denials are overturned on appeal

She was started on 10 mg metoclopramide as needed every six hours and maintenance fluid